Impacts of intravitreal anti-VEGF therapy on retinal anatomy and neurophysiology in diabetic macular edema

Basit Öğe Kaydı
dc.authoridDOĞAN, Mustafa/0000-0001-7237-9847
dc.authoridYozgat, Zübeyir/0000-0001-5248-5562
dc.authoridyazgan, serpil/0000-0001-6401-6376
dc.authoridSabaner, Mehmet Cem/0000-0002-0958-9961
dc.authoridGOBEKA, HAMIDU HAMISI/0000-0002-7656-3155
dc.authorwosidDOĞAN, Mustafa/N-9819-2019
dc.authorwosidYozgat, Zübeyir/JZT-0861-2024
dc.authorwosidyazgan, serpil/Z-1951-2019
dc.authorwosidSabaner, Mehmet Cem/AAI-1777-2020
dc.authorwosidGOBEKA, HAMIDU HAMISI/ABF-4732-2020
dc.contributor.authorYozgat, Zubeyir
dc.contributor.authorDogan, Mustafa
dc.contributor.authorSabaner, Mehmet Cem
dc.contributor.authorGobeka, Hamidu Hamisi
dc.contributor.authorYazgan Akpolat, Serpil
dc.date.accessioned2024-08-04T20:49:17Z
dc.date.available2024-08-04T20:49:17Z
dc.date.issued2021
dc.departmentİnönü Üniversitesien_US
dc.description.abstractPurpose To evaluate anatomical and neuroretinal functional aspects in patients with diabetic macular edema (DME) after intravitreal anti-vascular endothelial growth factor (VEGF) therapy, in particular aflibercept. Materials and methods This prospective single-centered interventional study was performed at Afyonkarahisar Health Science University Faculty of Medicine, Department of Ophthalmology, where 32 eyes of 32 patients with DME were investigated. All patients received five intravitreal aflibercept injections on a monthly basis and were followed up for >= 6 months. After a comprehensive ophthalmological examination, including the measurements of visual acuity and intraocular pressure, and an antero-posterior segment slit-lamp biomicroscopy before and after full pupil dilation, fundus fluorescein angiography and optical coherence tomography were performed at baseline and during the third and sixth months post-therapy. Microperimetry and multifocal electroretinography were also performed at baseline and during the sixth months. Results Mean visual acuity increased from 0.73 to 0.57 and 0.33 logarithm of the minimum angle of resolution (logMAR) during the third and sixth months, respectively (p < 0.001). Changes in intraocular pressure were not statistically significant (p = 0.472). There was statistically significantly decreased mean central macular thickness from 390.2 mu m to 242.6 and 289.7 mu m during the third and sixth months, respectively (p < 0.001). Significantly improved fixation patterns during the sixth month, along with significantly increased macular sensitivity from 8.2 to 14.2 dB (p < 0.001) and significantly decreased local deficit from - 10.3 to 5.5 dB (p < 0.001) were observed. Further, there was a significantly increased N1 amplitude in the first ring and significantly increased P1 amplitude in all rings (p for each parameter < 0.05). There was also significantly decreased N1 wave implicit time in all rings and significantly decreased P1 wave in the second, third, fourth and fifth rings (p for each parameter < 0.05). Conclusions Patients with DME showed profound improvement in the retinal neurophysiological function, which was also accompanied by anatomical and ultrastructural integrity recovery after intravitreal aflibercept therapy. In the pathogenesis of DME, the influence of neurodegeneration has been increasingly gaining significant attention. Consequently, the need to assess neurophysiological effects of anti-VEGF therapy using a variety of diagnostic measures like electrophysiological studies and multimodal imaging technologies is undeniably growing.en_US
dc.description.sponsorshipAfyon Kocatepe University [15]; (TUS.17)en_US
dc.description.sponsorshipThis study was funded by Afyon Kocatepe University (Grant Number 15.TUS.17).en_US
dc.identifier.doi10.1007/s10792-021-01737-w
dc.identifier.endpage1798en_US
dc.identifier.issn0165-5701
dc.identifier.issn1573-2630
dc.identifier.issue5en_US
dc.identifier.pmid33606153en_US
dc.identifier.scopus2-s2.0-85100974056en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage1783en_US
dc.identifier.urihttps://doi.org/10.1007/s10792-021-01737-w
dc.identifier.urihttps://hdl.handle.net/11616/99767
dc.identifier.volume41en_US
dc.identifier.wosWOS:000619695100002en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofInternational Ophthalmologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAflibercepten_US
dc.subjectDiabetic macular edemaen_US
dc.subjectFundus fluorescein angiographyen_US
dc.subjectMicroperimetryen_US
dc.subjectMultifocal electroretinographyen_US
dc.subjectOptical coherence tomographyen_US
dc.titleImpacts of intravitreal anti-VEGF therapy on retinal anatomy and neurophysiology in diabetic macular edemaen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu